Farxiga vs Trulicity
Side-by-side cost comparison based on Medicare Part D data
Farxiga
Dapagliflozin
Manufactured by AstraZeneca
Trulicity
Dulaglutide
Manufactured by Eli Lilly
Farxiga costs 44% less per claim than Trulicity ($266.00 vs $473.00). A generic version of Farxiga is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Farxiga | Trulicity |
|---|---|---|
| Avg Cost Per Claim | $266.00 | $473.00 |
| Total Medicare Spending | $3.0B | $4.2B |
| Total Beneficiaries | 1,340,000 | 985,000 |
| Total Claims | 11,240,000 | 8,920,000 |
| Annual Cost/Patient | $2,229.00 | $4,279.00 |
| Year-over-Year Change | +31.5% | -4.8% |
| Generic Available | Yes | No |
| Patent Expiration | Nov 13, 2025 | Sep 18, 2027 |
| Manufacturer | AstraZeneca | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Dapagliflozin | Dulaglutide |
Farxiga vs Trulicity: What the Data Shows
Farxiga (Dapagliflozin) and Trulicity (Dulaglutide) are both used to treat diabetes. Based on Medicare Part D data, Farxiga costs $266.00 per claim, which is 44% less than Trulicity at $473.00 per claim.
Medicare spent $3.0B on Farxiga and $4.2B on Trulicity. In terms of patient reach, Farxiga serves more beneficiaries (1,340,000 vs 985,000).
Year-over-year spending changed +31.5% for Farxiga and -4.8% for Trulicity. Farxiga saw significant spending growth, suggesting increased utilization or price increases.
Farxiga has a generic available, while Trulicity remains brand-only until its patent expires Sep 18, 2027.
Frequently Asked Questions
Farxiga is cheaper at $266.00 per claim, compared to $473.00 for Trulicity. That makes Farxiga about 44% less expensive per claim based on Medicare Part D data.
Yes, both Farxiga and Trulicity are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Farxiga has a generic version (Dapagliflozin) available, which is typically much cheaper. Trulicity is currently brand-only, with patent expiring Sep 18, 2027.
Medicare Part D spent $3.0B on Farxiga covering 1,340,000 beneficiaries, and $4.2B on Trulicity covering 985,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.